Kits Eyecare (KITS) AI Stock Analysis

• Market Cap: C$500.14M
• Dividend Yield: N/A
• Average Volume (3M): 53.64K
• Price to Earnings (P/E): 188.9
• Beta (1Y): 1.12
• Revenue Growth: 32.31%
• EPS Growth: N/A
• Country: CA
• Employees: 162
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Specialty Retail
• EPS (TTM): 0.06
• Shares Outstanding: 32,267,204
• 10 Day Avg. Volume: 77,427
• 30 Day Avg. Volume: 53,639
• PEG Ratio: -103.69
• Price to Book (P/B): 9.43
• Price to Sales (P/S): 2.90
• P/FCF Ratio: 51.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$24.58
• Price Target Upside: 58.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 0.27
• Revenue Forecast (FY): C$249.91M

• Rating: 64 Neutral
• Price Target: C$17.00 ▲(9.68% Upside)
• Action: Downgraded Date: 03/06/26
• Date: Action: Downgraded 03/06/26

The score is driven primarily by improving financial performance (profitability and cash-flow turnaround) and a positive earnings update with continued growth and margin progress. Offsetting these positives are weak technicals (broadly below key moving averages with negative MACD) and a very high P/E that increases valuation risk.

Positive Factors

Sustained Revenue & Customer Scale

Sustained top-line scale and accelerating customer additions signal durable demand and improving unit economics. A growing active base (1M+) reduces reliance on single purchases, spreads marketing fixed costs, and supports repeat revenue, enhancing long-term growth and margin resilience.

High‑margin Contact Lens Growth

Rapid expansion of a high‑margin, repeat purchase category shifts revenue mix toward more profitable, recurring sales. Contact lenses' >50% gross margin and strong growth materially improve structural profitability and cash generation potential over coming quarters.

Improving Cash Generation & Manageable Leverage

Reliable free cash flow and strong cash conversion in 2024–25 provide financial flexibility to fund marketing, product investment, or M&A. Coupled with debt at roughly a quarter of equity, this supports capital allocation and lowers external financing dependence over a medium-term horizon.

Negative Factors

Thin Net Profitability

Low single‑digit net margins leave limited cushion against cost inflation, promotional pressure, or higher fulfilment expenses. Small margin buffers increase the risk that short to medium-term headwinds could erase profits and impair free cash flow consistency.

Historic Financial Volatility

A history of balance‑sheet stress and prior negative equity highlights cyclical vulnerability. Past negative operating and free cash flow years imply performance can reverse in downturns, raising the bar for consistent capital returns and long‑term stability.

Constrained U.S. Expansion / Regulatory Uncertainty

Pulling back U.S. investment limits addressable market diversification and scale economies. Regulatory uncertainty and measured U.S. spend slow international expansion, concentrating growth in Canada and increasing reliance on a narrower market for sustaining revenue momentum.

Kits Eyecare Business Overview & Revenue Model

Company Description

Kits Eyecare Ltd. operates a digital eyecare platform for eyes in the United States and Canada. The company manufactures progressive and contact lenses, eyeglasses, and frames under the KITS brand, as well as distributes eyewear products of various brands. It operates through a network of optical e-commerce websites, including KITS.com, KITS.ca, OptiContacts.com, and ContactsExpress.ca. The company was incorporated in 2018 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Kits Eyecare generates revenue primarily through the sale of prescription eyewear, including glasses and contact lenses, as well as non-prescription sunglasses. The company operates on a direct-to-consumer model, which allows it to offer competitive pricing by eliminating middlemen costs. Key revenue streams include the sale of eyewear products and potential subscription services for contact lenses. Additionally, KITS may form partnerships with eyewear manufacturers and optical labs to enhance its product offerings and streamline supply chain operations, thereby contributing to its earnings. Marketing strategies, such as targeted advertising and promotions, also play a crucial role in driving sales and customer acquisition.

Kits Eyecare Financial Statement Overview

Summary

Financials show a multi-year turnaround with scaled revenue, improving profitability, and solid 2024–2025 operating/free cash flow. Key risks are thin net margins and historical volatility in earnings and cash generation.

Income Statement

Kits Eyecare shows a clear earnings turnaround: net results improved from losses in 2021–2023 to profits in 2024–2025, alongside steady improvement in operating profitability. Revenue has scaled meaningfully over the period, with growth re-accelerating in 2025. Gross margin has also expanded versus earlier years, supporting the move into positive operating income. The main weakness is that net profitability remains thin (low single-digit net margin), leaving results more sensitive to cost pressure or demand softness than higher-margin peers.

Balance Sheet

Leverage appears manageable with debt at roughly a quarter of equity in 2024–2025, and equity has grown over time, supporting a stronger capital base. Returns on equity have shifted from negative in 2021–2023 to modestly positive in 2024–2025, consistent with the profitability recovery. The key watch-out is historical volatility (including a period of negative equity in 2020), which highlights that while the balance sheet is currently healthier, it has been through stress in the past.

Cash Flow

Cash generation is a strength: operating cash flow and free cash flow are solidly positive in 2024–2025, and free cash flow growth accelerated sharply in 2025. Cash conversion quality is also good, with free cash flow roughly matching reported earnings in 2025 (and strong in 2024), suggesting profits are supported by real cash. The primary weakness is variability across the cycle, including negative operating and free cash flow in 2021 and relatively low operating cash flow levels in 2022–2023.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	202.46M	159.34M	120.51M	91.64M	82.40M
Gross Profit	71.28M	53.65M	40.79M	29.25M	20.89M
EBITDA	10.64M	8.31M	1.86M	-721.00K	-14.25M
Net Income	3.11M	3.12M	-2.21M	-4.55M	-14.62M
Balance Sheet
Total Assets	112.96M	103.02M	87.64M	93.86M	90.94M
Cash, Cash Equivalents and Short-Term Investments	33.67M	19.27M	16.04M	18.79M	20.50M
Total Debt	15.82M	12.60M	15.39M	19.44M	22.94M
Total Liabilities	50.65M	45.13M	36.20M	40.16M	36.16M
Stockholders Equity	62.31M	57.89M	51.45M	53.71M	54.78M
Cash Flow
Free Cash Flow	11.33M	9.88M	1.84M	4.42M	-23.09M
Operating Cash Flow	11.46M	13.04M	2.40M	4.68M	-19.46M
Investing Cash Flow	-5.13M	-3.15M	-563.00K	-258.00K	-3.63M
Financing Cash Flow	3.47M	-5.02M	-5.07M	-5.13M	41.48M

Kits Eyecare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KITS, the sentiment is Negative. The current price of 15.5 is below the 20-day moving average (MA) of 18.28, below the 50-day MA of 19.31, and below the 200-day MA of 16.35, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 28.50 is Positive, neither overbought nor oversold. The STOCH value of 26.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KITS.

Kits Eyecare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATD	77 Outperform	C$74.19B	22.62	17.53%	1.08%	2.25%	4.76%
LNF	67 Neutral	C$1.85B	12.20	15.07%	3.11%	1.99%	31.36%
KITS	64 Neutral	C$500.14M	188.91	9.68%	―	32.31%	―
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
ECOM	57 Neutral	C$16.44M	106.09	―	―	24.43%	―
PET	57 Neutral	C$1.67B	19.75	106.59%	1.72%	5.09%	14.05%
CTC	55 Neutral	C$10.26B	16.32	13.16%	3.17%	-0.13%	13.73%

Kits Eyecare Corporate Events

Kits Eyecare Hits Record 2025 Revenue as Eyeglasses and AI Platform Drive Growth

Kits Eyecare reported record 2025 results, with annual revenue rising 27.1% to $202.5 million, gross margin expanding to 35.6%, and adjusted EBITDA climbing 82.6% to $11.7 million while delivering over 426,000 pairs of glasses. The company achieved its 13th consecutive quarter of positive adjusted EBITDA, surpassed one million active customers, generated $11.5 million in operating cash flow, and highlighted strong eyeglasses growth and repeat-order dynamics that reinforce its technology-led, vertically integrated model and support its strategy to scale both digital and physical channels.

In the fourth quarter, revenue grew 20.2% to $53.9 million, driven by record glasses revenue of $8.7 million and strong Black Friday and Cyber Monday sales, while maintaining profitability with $2.8 million in adjusted EBITDA and $0.3 million in net income. Management emphasized that new platforms such as OpticianAI and AI-driven smart glasses, combined with a de-risked balance sheet and additional showrooms, are broadening its competitive moat and positioning the company to create additional value for customers and shareholders.

The most recent analyst rating on (TSE:KITS) stock is a Buy with a C$25.00 price target. To see the full list of analyst forecasts on Kits Eyecare stock, see the TSE:KITS Stock Forecast page.